[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100263220":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":58,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Institute of Cancer Research, United Kingdom","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Mutation carriers with Prostate cancer",null,"Men with prostate cancer and a known pathogenic germline mutation in:\n\n1. the BRCA1 or BRCA2 gene\n2. the HOXB13 gene\n3. The MSH2 gene\n4. All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM)\n5. The ATM gene\n6. Other PCa predisposition genes",[13],"Other: Observation of treatment outcomes via Questionnaire",{"label":15,"type":10,"description":16,"interventionNames":17},"Mutation non carriers","Men with prostate cancer who have tested negative for a mutation in one of the following genes:\n\n1. the BRCA1 or BRCA2 gene\n2. the HOXB13 gene\n3. The MSH2 gene\n4. All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM)\n5. The ATM gene\n6. Other PCa predisposition genes",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Observation of treatment outcomes via Questionnaire","Collection of treatment data from participants",[9,15],[24],{"name":25,"affiliation":5,"role":26},"Rosalind A Eeles, PhD","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Elizabeth C Page, MSc","CONTACT","44 208 722 4483","elizabeth.page@icr.ac.uk",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"Elizabeth Bancroft, PhD","elizabeth.bancroft@rmh.nhs.uk",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Institute of Cancer Research and Royal Marsden Hospital","RECRUITING","Sutton","Surrey","SM2 5PT","United Kingdom","UK",{"type":46,"coordinates":47},"Point",[48,49],-0.2,51.35,{"lat":49,"lon":48},[52,56],{"name":53,"role":30,"phone":54,"phoneExt":10,"email":55},"Rosalind A Eeles, FRCP FRFR","02086613642","rosalind.eeles@icr.ac.uk",{"name":57,"role":26,"phone":10,"phoneExt":10,"email":10},"Rosalind A Eeles, FRCP FRCR",{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100263220","analysing-outcomes-after-prostate-cancer-diagnosis-and-treatment-in-carriers-of-rare-germline-mutations-100263220",false,"NCT02705846","Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations","Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutation in Cancer Predisposition Genes","GENPROS","Inclusion Criteria:\n\n* Men diagnosed with PCa are eligible if:\n* known carriers of germline mutations associated with PCa risk OR\n* known non-carriers of mutations in the genes above\n\nExclusion Criteria:\n\n* patients under 18 years of age\n* patients who are unable to give informed consent\n* patients who cannot be traced (\\\u003C6 months follow-up) or whose clinical data are not available\n* patients whose genetic status is unknown","MALE","18 Years",{"count":71,"type":72},4260,"ESTIMATED","OBSERVATIONAL","GENPROS aims to analyse the outcomes of patients with rare gene mutations in the cancer predisposition genes, BRCA1, BRCA2, HOXB13, and Lynch Syndrome, after a diagnosis of and treatment for prostate cancer (PCa). The study includes a cohort of gene mutation carriers with PCa matched with a control group of men with PCa who are known not to carry a mutation in the same gene. Clinical data regarding treatment and patient outcome will be collected retrospectively and prospectively. Archived tumour samples will also be collected for tumour profiling. A blood or saliva sample will be taken, if the participant consents to this part of the study, for genetic profiling to investigate any association of other inherited factors with PCa outcomes. Information obtained from this study will be of critical importance to support clinical trials investigating the most appropriate management of PCa in this group of patients at increased risk of prostate cancer.",[76],"Prostate Cancer",[78,79,80,81],"BRCA1","BRCA2","Lynch Syndrome","Genetic predisposition to Prostate cancer","2025-09-25",{"date":84,"type":85},"2025-09-26","ACTUAL",{"date":87,"type":10},"2014-09",{"date":89,"type":72},"2035-12",{"name":5,"class":6},1]